Hypertension Management Guidelines

ACC/AHA Blood Pressure Guidelines Summary

Classification:
- Normal: <120/<80 mmHg
- Elevated: 120-129/<80 mmHg
- Stage 1 HTN: 130-139/80-89 mmHg
- Stage 2 HTN: ≥140/≥90 mmHg

Treatment Targets:
- General population: <130/80 mmHg
- CKD: <130/80 mmHg
- Diabetes: <130/80 mmHg
- Elderly (>65): Consider <130/80 if tolerated

Initial Treatment:

Non-pharmacologic:
- Weight loss if overweight
- DASH diet
- Sodium restriction (<2g/day)
- Exercise (150 min/week moderate activity)
- Limit alcohol

Pharmacologic:
- Stage 1 HTN + ASCVD risk ≥10%: Start medication
- Stage 2 HTN: Start medication regardless of risk

First-Line Agents:
1. Thiazide diuretics (chlorthalidone, HCTZ)
2. ACE inhibitors (lisinopril, enalapril)
3. ARBs (losartan, valsartan)
4. Calcium channel blockers (amlodipine)

Special Populations:

CKD:
- ACE inhibitor or ARB preferred
- Monitor K+ and creatinine
- May need additional agents

Diabetes:
- ACE inhibitor or ARB preferred
- Target <130/80

Heart Failure:
- ACE inhibitor/ARB + beta-blocker + diuretic
- Consider ARNI (sacubitril-valsartan)

Black Patients:
- Thiazide or CCB as initial therapy
- ACE/ARB if CKD present

Monitoring:
- Monthly until controlled
- Every 3-6 months once stable
- Home BP monitoring encouraged
- Check for end-organ damage

Resistant Hypertension:
- 3 agents at optimal doses (including diuretic)
- Check adherence
- Screen for secondary causes
- Consider mineralocorticoid receptor antagonist

References: ACC/AHA 2023, JNC 8

